“…Currently, in the United States, most RHD genotyping is performed in reference laboratories and, therefore, the turnaround time is more than 1 day, excluding the procedure for patients requiring an urgent transfusion. For patients requiring chronic transfusions, for example, sickle cell disease, thalassaemia and myelodysplastic syndrome, the results of once-in-a-lifetime RHD genotyping may not be available in time for the current transfusion, but would be available for future transfusions (Chou et al, 2013;Fasano & Chou, 2016 to minutes, making RHD genotyping feasible for real-time application in the hospital (Wagner et al, 2017). Patients with sickle cell disease benefit from RHD genotyping, not only because most have a requirement for chronic transfusion, but also because they are at increased risk of alloimmunization to certain Rh and other blood group antigens because of the differences that they inherit from their African ancestry compared to those inherited by the predominately Caucasian donors in Western countries (Vichinsky et al, 1990).…”